Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29462393 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL18462460 | 0.85 | ALDH1A1 (0.47) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL30014602 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL20595552 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL13407323 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL5008175 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL1693396 | 0.80 | ALDH1A1 (0.54) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL13274269 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL25366611 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA | |
| SCHEMBL1629347 | 0.78 | ALDH1A1 (0.42) | ALDH1A1MAPTSMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) | 2026-04-23 | — | — | US | disclosed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | BOEHRINGER INGELHEIM INT (DE) | 2026-03-19 | — | — | US | disclosed |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | TERREMOTO BIOSCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260049093-A1 | Bicyclic Ureas As Kinase Inhibitors | INCYTE CORP (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2025081045-A9 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | GALAPAGOS NV (BE) | 2025-11-18 | — | — | US | disclosed |
| US-20250325544-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | TERREMOTO BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250281487-A1 | CDK INHIBITORS | GENENTECH, INC. (US) | 2025-09-11 | — | — | US | disclosed |
| WO-2006031491-A2 | TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006013195-A1 | 5-SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINES | ALTANA PHARMA AG (DE) | 2006-02-09 | — | — | WO | disclosed |
| EP-1581539-A2 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| WO-2004063151-A2 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| US-5863916-A | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER-EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON (US) | 1999-01-26 | — | — | US | disclosed |
| US-5620978-A | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor | STATE OF OREGON, ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION, ACTING FOR AND ON BEHALF OF THE OREGON HEALTH SCIENCES UNIVERSITY AND THE UNIVERSITY OF OREGON, EUGENE OREGON (US) | 1997-04-15 | — | — | US | disclosed |
| EP-0743855-A1 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARMACEUTICALS, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| WO-1995018616-A2 | 8-AZA, 6-AZA AND 6,8-DIAZA-1,4-DIHYDROQUINOXALINE-2,3-DIONES AND THE USE THEREOF AS ANTAGONISTS FOR THE GLYCINE/NMDA RECEPTOR | ACEA PHARM INC (US) | 1995-07-13 | — | — | WO | disclosed |
| US-4068085-A | YELLOW AND RED ON POLYESTERS AND ACRYLICS | CIBA-GEIGY CORPORATION (US) | 1978-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281487-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | ALDH1A1 2343/4885MAPT 2063/4885SMN1; SMN2 2041/4885 |
| US-20260049093-A1 | Bicyclic Ureas As Kinase Inhibitors | OXSR1, JAK1, NCOR1 | ALDH1A1 1726/4885MAPT 4260/4885SMN1; SMN2 1686/4885 |
| US-20260109715-A1 | IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE | SMG1, RACK1, TIA1 | ALDH1A1 2420/4885MAPT 4730/4885SMN1; SMN2 469/4885 |
| US-20260078127-A1 | HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 | CD38, CD22, CD79B | ALDH1A1 877/4885MAPT 4832/4885SMN1; SMN2 3935/4885 |
| US-20040180897-A1 | Novel tyrosine kinase inhibitors | ABL1, ROS1, YES1 | ALDH1A1 1254/4885MAPT 4438/4885SMN1; SMN2 4504/4885 |
| US-12570655-B2 | Cysteine covalent modifiers of AKT1 and uses thereof | AKT1, AKT2, AKT3 | ALDH1A1 3594/4885MAPT 4745/4885SMN1; SMN2 4318/4885 |
| US-20250325544-A1 | CDK INHIBITORS | CDK6, CDK9, CDKL1 | ALDH1A1 2343/4885MAPT 2063/4885SMN1; SMN2 2041/4885 |
| US-20250289819-A1 | CYSTEINE COVALENT MODIFIERS OF AKT1 AND USES THEREOF | AKT1, AKT2, AKT3 | ALDH1A1 3008/4885MAPT 3989/4885SMN1; SMN2 4603/4885 |
| US-12472181-B2 | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders | IL15, IL2, IL33 | ALDH1A1 784/4885MAPT 4506/4885SMN1; SMN2 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.